Clinical Trial Update: Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing irinotecan hydrochloride (Campto) plus cisplatin vs etoposide plus cisplatin in small cell lung cancer has completed and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Etoposide (Etoposide)
• Irinotecan hydrochloride (Campto) (irinotecan)

Snippet

Sponsor: Pfizer | Conditions: Small Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2010-01-21